CL2009001082A1 - Procedimiento para tratar artritis indiferenciada que comprende administrar una molecula de ctla4 que se une a cd80 y/o cd86. - Google Patents

Procedimiento para tratar artritis indiferenciada que comprende administrar una molecula de ctla4 que se une a cd80 y/o cd86.

Info

Publication number
CL2009001082A1
CL2009001082A1 CL2009001082A CL2009001082A CL2009001082A1 CL 2009001082 A1 CL2009001082 A1 CL 2009001082A1 CL 2009001082 A CL2009001082 A CL 2009001082A CL 2009001082 A CL2009001082 A CL 2009001082A CL 2009001082 A1 CL2009001082 A1 CL 2009001082A1
Authority
CL
Chile
Prior art keywords
binds
administering
ctla4
molecule
undifferentiated arthritis
Prior art date
Application number
CL2009001082A
Other languages
English (en)
Spanish (es)
Inventor
Michael Corbo
George Vratsanos
Jean-Claude Becker
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41264941&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2009001082(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CL2009001082A1 publication Critical patent/CL2009001082A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
CL2009001082A 2008-05-05 2009-05-05 Procedimiento para tratar artritis indiferenciada que comprende administrar una molecula de ctla4 que se une a cd80 y/o cd86. CL2009001082A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5033608P 2008-05-05 2008-05-05
US12/387,359 US7915222B2 (en) 2008-05-05 2009-05-01 Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis

Publications (1)

Publication Number Publication Date
CL2009001082A1 true CL2009001082A1 (es) 2010-02-12

Family

ID=41264941

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2009001082A CL2009001082A1 (es) 2008-05-05 2009-05-05 Procedimiento para tratar artritis indiferenciada que comprende administrar una molecula de ctla4 que se une a cd80 y/o cd86.

Country Status (25)

Country Link
US (3) US7915222B2 (OSRAM)
EP (2) EP2891665A1 (OSRAM)
JP (1) JP2011522795A (OSRAM)
KR (1) KR20110014180A (OSRAM)
CN (1) CN102037010A (OSRAM)
AR (1) AR071672A1 (OSRAM)
AU (1) AU2009244448B2 (OSRAM)
BR (1) BRPI0912249A2 (OSRAM)
CA (1) CA2723698C (OSRAM)
CL (1) CL2009001082A1 (OSRAM)
DK (1) DK2279206T3 (OSRAM)
EA (1) EA201001749A1 (OSRAM)
ES (1) ES2539840T3 (OSRAM)
HK (1) HK1208230A1 (OSRAM)
HR (1) HRP20150552T1 (OSRAM)
HU (1) HUE025256T2 (OSRAM)
IL (1) IL208691A (OSRAM)
MX (1) MX2010011503A (OSRAM)
NZ (1) NZ589020A (OSRAM)
PL (1) PL2279206T3 (OSRAM)
PT (1) PT2279206E (OSRAM)
SI (1) SI2279206T1 (OSRAM)
TW (2) TWI454278B (OSRAM)
WO (1) WO2009137424A1 (OSRAM)
ZA (1) ZA201007914B (OSRAM)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040022787A1 (en) * 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
US7915222B2 (en) * 2008-05-05 2011-03-29 Bristol-Myers Squibb Company Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis
CA2851322C (en) * 2011-10-10 2020-03-31 Medimmune Limited Treatment for rheumatoid arthritis with gm csfr alpha antibodies
US20140006055A1 (en) * 2012-06-27 2014-01-02 Iagnosis, Inc. Integrated Medical Evaluation and Record Keeping System
WO2014070840A2 (en) * 2012-10-30 2014-05-08 Emory University Stimulating bone formation by inhibition of cd28 co-stimulation
WO2014151230A2 (en) * 2013-03-15 2014-09-25 Bristol-Myers Squibb Company Method of treating granulomatosis with polyangiitis
EP3134109A1 (en) * 2014-04-25 2017-03-01 Bristol-Myers Squibb Company Use of ctla4 compound for achieving drug-free remission in subjects with early ra
PT3283508T (pt) 2015-04-17 2021-06-21 Alpine Immune Sciences Inc Proteínas imuno modulatórias com afinidades afináveis
CA3198255A1 (en) 2017-10-10 2019-04-18 Alpine Immune Sciences, Inc. Ctla-4 variant immunomodulatory proteins and uses thereof
WO2019136179A1 (en) 2018-01-03 2019-07-11 Alpine Immune Sciences, Inc. Multi-domain immunomodulatory proteins and methods of use thereof
CN110148465B (zh) * 2019-05-10 2023-07-04 中山大学孙逸仙纪念医院 一种用于分析类风湿性关节炎的系统

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5580756A (en) * 1990-03-26 1996-12-03 Bristol-Myers Squibb Co. B7Ig fusion protein
US7070776B1 (en) * 1990-03-26 2006-07-04 Bristol-Myers Squibb Company Methods for blocking binding of CD28 receptor to B7
KR100238712B1 (ko) * 1991-06-27 2000-01-15 스티븐 비. 데이비스 씨티엘에이4 수용체,그를 함유한 연합단백질 및 그의 용도
US5770197A (en) * 1991-06-27 1998-06-23 Bristol-Myers Squibb Company Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules
US5851795A (en) * 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US5844095A (en) * 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
US6090914A (en) * 1991-06-27 2000-07-18 Bristol-Myers Squibb Company CTLA4/CD28Ig hybrid fusion proteins and uses thereof
CA2154487A1 (en) * 1993-01-21 1994-08-04 Nicholas S. Hill Vaccines and methods for preventing and treating fescue toxicosis in herbivores
US5773253A (en) * 1993-01-22 1998-06-30 Bristol-Myers Squibb Company MYPPPY variants of CTL A4 and uses thereof
US6750334B1 (en) * 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
IL125928A (en) * 1996-03-20 2002-11-10 Bristol Myers Squibb Co The use of soluble ligands that react with CTLA4, B7, CD40, gp39 and / or CD28 for the preparation of pharmaceutical preparations
ZA98533B (en) * 1997-01-31 1999-07-22 Bristol Myers Squibb Co Soluble CTLA4 mutant molecules and uses thereof.
US20030219863A1 (en) * 1997-01-31 2003-11-27 Bristol-Myers Squibb Company Soluble CTLA4 mutant molecules and uses thereof
US7094874B2 (en) * 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
MXPA02012157A (es) * 2000-06-09 2003-06-06 Bristol Myers Squibb Co Metodos para regular una respuesta inmune mediada por celulas al bloquear se°ales linfociticas y al bloquear la adhesion mediada por el antigeno 1 asociado con la funcion de linfocitos.
ATE401909T1 (de) * 2000-07-03 2008-08-15 Bristol Myers Squibb Co Verwendung von löslichen ctla4-mutanten zur behandlung von rheumatoider arthritis
US20040022787A1 (en) * 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
HUP0303930A3 (en) * 2001-01-26 2012-09-28 Univ Emory Methods of inducing organ transplant tolerance and correcting hemoglobinopathies
ATE390931T1 (de) * 2001-05-23 2008-04-15 Bristol Myers Squibb Co Verfahren zum schützen eines allogenen inseltransplantats mit löslichen ctla4- mutationsmolekülen
JP4541157B2 (ja) * 2002-12-23 2010-09-08 ブリストル−マイヤーズ スクイブ カンパニー タンパク質を製造するための哺乳類細胞培養法
ES2354610T5 (es) * 2002-12-23 2020-09-14 Bristol Myers Squibb Co Mejora de la calidad del producto en procedimientos de cultivo de células de mamífero para la producción de proteína
JP2007501243A (ja) * 2003-08-04 2007-01-25 ブリストル−マイヤーズ　スクイブ　カンパニー 可溶性ｃｔｌａ４分子を用いる心臓血管疾患の治療方法
BRPI0611707A2 (pt) 2005-06-29 2012-04-24 Compumedics Ltd conjunto de sensor com ponte condutiva
WO2007024964A1 (en) * 2005-08-22 2007-03-01 Incept, Llc Flared stents and apparatus and methods for making and using them
JP5096369B2 (ja) 2005-12-20 2012-12-12 ブリストル−マイヤーズ スクイブ カンパニー 組成物および組成物の製造方法
CN101584858A (zh) 2005-12-20 2009-11-25 布里斯托尔-迈尔斯斯奎布公司 稳定蛋白质制剂
US7528111B2 (en) * 2006-05-12 2009-05-05 Bristol-Myers Squibb Company Method of vaccinating subjects receiving immune modulating therapy
US7915222B2 (en) * 2008-05-05 2011-03-29 Bristol-Myers Squibb Company Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis

Also Published As

Publication number Publication date
SI2279206T1 (sl) 2015-08-31
JP2011522795A (ja) 2011-08-04
US20130195865A1 (en) 2013-08-01
BRPI0912249A2 (pt) 2015-10-20
AU2009244448A1 (en) 2009-11-12
US7915222B2 (en) 2011-03-29
CA2723698A1 (en) 2009-11-12
IL208691A (en) 2015-01-29
PL2279206T3 (pl) 2015-09-30
CN102037010A (zh) 2011-04-27
MX2010011503A (es) 2010-11-09
AR071672A1 (es) 2010-07-07
WO2009137424A1 (en) 2009-11-12
US9012408B2 (en) 2015-04-21
US20090280119A1 (en) 2009-11-12
HK1148291A1 (en) 2011-09-02
HUE025256T2 (en) 2016-02-29
HK1208230A1 (en) 2016-02-26
TW201444575A (zh) 2014-12-01
CA2723698C (en) 2018-03-06
ZA201007914B (en) 2011-07-27
PT2279206E (pt) 2015-07-27
AU2009244448B2 (en) 2014-07-31
EP2891665A1 (en) 2015-07-08
TWI454278B (zh) 2014-10-01
US8435952B2 (en) 2013-05-07
EP2279206A1 (en) 2011-02-02
DK2279206T3 (en) 2015-07-27
EP2279206B1 (en) 2015-04-22
IL208691A0 (en) 2010-12-30
HRP20150552T1 (hr) 2015-06-19
US20110142835A1 (en) 2011-06-16
NZ589020A (en) 2012-05-25
TW200948381A (en) 2009-12-01
ES2539840T3 (es) 2015-07-06
EA201001749A1 (ru) 2011-06-30
KR20110014180A (ko) 2011-02-10
EP2279206A4 (en) 2011-05-25

Similar Documents

Publication Publication Date Title
CL2009001082A1 (es) Procedimiento para tratar artritis indiferenciada que comprende administrar una molecula de ctla4 que se une a cd80 y/o cd86.
MX2010009765A (es) Moleculas pequeñas que contienen boro como agentes anti-inflamatorios.
BR112012016742A2 (pt) metodos para tratamento de cancer pancreatico
CO2018001149A2 (es) Anticuerpos monoclonales contra bcma
BR112012015501A8 (pt) Processo de biodegradação e composição
CL2018000108A1 (es) Moléculas de anticuerpo que se unen a cd22
MX2013008376A (es) Composiciones y metodos para el tratamiento de cancer.
BR112013016242A2 (pt) método de cimentação e, composição de cimentação
AU2016204248A1 (en) Boron-Containing Molecules
CR20140232A (es) Agentes de iarn, composiciones y métodos de uso de los mismos para tratar enfermedades asociadas con transtiretina (ttr)
BR112014028644A2 (pt) Composições e métodos para modulação da expressão de atp2a2
CL2016000839A1 (es) Composiciones para modular la expresión de c9orf72.
BR112012016471A2 (pt) método para cimentação em uma formação subterrânea, e, composição de cimento
BR112016003127A2 (pt) “composições e métodos para modular rna”
CR20160206A (es) Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento C5
WO2009111676A8 (en) Boron-containing small molecules as anti-inflammatory agents
BR112017008914A2 (pt) método para tratar câncer, composição e uso da composição
MX373763B (es) Uso de una composición de combinación de acamprosato y baclofeno de liberación sostenida, para el tratamiento de esclerosis lateral amiotrófica.
MX2015012401A (es) Composiciones y metodos de alterar niveles de colesterol.
SG169988A1 (en) Rnai inhibition of alpha-enac expression
MX374826B (es) Un anticuerpo biespecífico que se une a pcrv y psl de pseudomonas.
AR088920A1 (es) Purificacion de anticuerpos anti-c-met
BRPI0715408B8 (pt) Processo para a preparação de 5-(1-alquiltio)alquilpiridinas 2-substituída
MX361299B (es) Metodo para activar celulas auxiliares.
EA201491286A1 (ru) Способ лечения потери костной массы альвеолярного отростка посредством применения антител к склеростину